WO2011111070A3 - Novel injectable combination - Google Patents

Novel injectable combination Download PDF

Info

Publication number
WO2011111070A3
WO2011111070A3 PCT/IN2011/000159 IN2011000159W WO2011111070A3 WO 2011111070 A3 WO2011111070 A3 WO 2011111070A3 IN 2011000159 W IN2011000159 W IN 2011000159W WO 2011111070 A3 WO2011111070 A3 WO 2011111070A3
Authority
WO
WIPO (PCT)
Prior art keywords
combination
novel injectable
injectable combination
formulation
novel
Prior art date
Application number
PCT/IN2011/000159
Other languages
French (fr)
Other versions
WO2011111070A2 (en
Inventor
Dharmesh Mahendrabhai Shah
Guruprasad Ramchandra Wader
Trushit Pramodray Mehta
Original Assignee
Bdr Pharmaceuticals International Pvt. Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bdr Pharmaceuticals International Pvt. Ltd. filed Critical Bdr Pharmaceuticals International Pvt. Ltd.
Publication of WO2011111070A2 publication Critical patent/WO2011111070A2/en
Publication of WO2011111070A3 publication Critical patent/WO2011111070A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4152—1,2-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. antipyrine, phenylbutazone, sulfinpyrazone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
    • A61K31/6615—Compounds having two or more esterified phosphorus acid groups, e.g. inositol triphosphate, phytic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions

Abstract

Disclosed herein is a stable injectable formulation comprising combination of Citicoline and Edaravone along with Cyclodextrin derivative, useful for the treatment of CNS disorders and ischemic strokes and further discloses a process of preparation of the said formulation.
PCT/IN2011/000159 2010-03-09 2011-03-09 Novel injectable combination WO2011111070A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN2592/MUM/2009 2010-03-09
IN2592MU2009 2010-03-09

Publications (2)

Publication Number Publication Date
WO2011111070A2 WO2011111070A2 (en) 2011-09-15
WO2011111070A3 true WO2011111070A3 (en) 2011-12-22

Family

ID=44563942

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IN2011/000159 WO2011111070A2 (en) 2010-03-09 2011-03-09 Novel injectable combination

Country Status (1)

Country Link
WO (1) WO2011111070A2 (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103006550A (en) * 2012-12-11 2013-04-03 哈药集团三精制药股份有限公司 Citicoline sodium injection and preparation method thereof
CN103351342B (en) * 2013-07-03 2015-08-05 浙江中医药大学 A kind of Edaravone pharmaceutical co-crystal and preparation method thereof
CN105012230B (en) * 2014-04-30 2018-01-16 长春海悦药业股份有限公司 A kind of pharmaceutical composition of Edaravone
CN104490771A (en) * 2014-12-19 2015-04-08 成都天台山制药有限公司 Citicoline Sodium injection pharmaceutical composition and preparation method thereof
CN110090225B (en) * 2019-04-19 2021-07-16 济南康和医药科技有限公司 Edaravone sodium chloride injection and preparation method thereof
CN111840220B (en) * 2020-08-19 2022-09-30 开封康诺药业有限公司 Citicoline sodium injection and preparation method thereof

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040142906A1 (en) * 2001-09-24 2004-07-22 Yanming Wang Conpositions and method to prevent and treat brain and spinal cord injuries
US20060264357A1 (en) * 1997-04-22 2006-11-23 Zikria Bashir A Capillary membrane stabilization and reduction of tissue injury through use of biodegradable macromolecules with antioxidants and/or other chemicals
US20080312226A1 (en) * 2004-11-18 2008-12-18 Takeda Pharmaceutical Company Limited Amide Compound
US20090163476A1 (en) * 2005-03-03 2009-06-25 Sirtris Pharmaceuticals, Inc. N-Phenyl Benzamide Derivatives as Sirtuin Modulators
US20090325862A1 (en) * 2006-05-04 2009-12-31 Christian Steinkuhler Histone Deacetylase Inhibitors for the Treatment of Neurodegeneration

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060264357A1 (en) * 1997-04-22 2006-11-23 Zikria Bashir A Capillary membrane stabilization and reduction of tissue injury through use of biodegradable macromolecules with antioxidants and/or other chemicals
US20040142906A1 (en) * 2001-09-24 2004-07-22 Yanming Wang Conpositions and method to prevent and treat brain and spinal cord injuries
US20080312226A1 (en) * 2004-11-18 2008-12-18 Takeda Pharmaceutical Company Limited Amide Compound
US20090163476A1 (en) * 2005-03-03 2009-06-25 Sirtris Pharmaceuticals, Inc. N-Phenyl Benzamide Derivatives as Sirtuin Modulators
US20090325862A1 (en) * 2006-05-04 2009-12-31 Christian Steinkuhler Histone Deacetylase Inhibitors for the Treatment of Neurodegeneration

Also Published As

Publication number Publication date
WO2011111070A2 (en) 2011-09-15

Similar Documents

Publication Publication Date Title
WO2012156998A3 (en) Amorphous mirabegron and processes for crystal forms of mirabegron
WO2015085318A3 (en) Targeted adaptive vaccines
MY176814A (en) Compounds and pharmaceutical compositions thereof for the treatment of cystic fibrosis
WO2012076466A3 (en) Substituted 1-benzylcycloalkylcarboxlic acids and use thereof
WO2011138281A3 (en) Process for the preparation of dithiine tetracarboxydiimides
WO2011111070A3 (en) Novel injectable combination
WO2015008218A3 (en) Process for the preparation of suvorexant and intermediates useful in the synthesis of suvorexant
AP2014007436A0 (en) A novel 1,2,3,4,-Tetrahydroquinoline derivative useful for the treatment of diabetes
WO2011009938A3 (en) Stambomycin and derivatives, their production and their use as drugs
WO2010102778A3 (en) Substituted 3-aminoisoxazolopyridines as kcnq2/3 modulators
WO2013003669A3 (en) Compositions, methods of use, and methods of treatment
WO2014036502A8 (en) Tetracycline compounds
WO2015037016A3 (en) An improved process for the preparation of ticagrelor and intermediates thereof
HK1199242A1 (en) Process for the production of 1,3-butadiene 13-
WO2011136513A3 (en) Bone-transplant or bone-filling composition comprising a dihydroxybenzoic acid derivative
BR112012027144A2 (en) tomato derived thickening agent, process for preparing a tomato derived thickening agent, method for preparing a food product and tomato ketchup product obtainable by the process
WO2015052568A3 (en) Solid forms of curcumin and derivatives thereof
WO2014195977A3 (en) Novel polymorphs of vismodegib
WO2015087343A3 (en) An improved process for the preparation of nilotinib and pharmaceutically acceptable salts thereof
WO2014030173A3 (en) Improved process for preparation of atazanavir bisulfate
WO2012159981A3 (en) PROCESS FOR THE PREPARATION OF α-SUBSTITUTED KETONES AND THEIR APPLICATION IN SYNTHESIS OF PHARMACEUTICALLY ACTIVE COMPOUNDS
WO2012104874A3 (en) Aqueous concentrated formulation of linezolid
WO2013113037A8 (en) Improved 1, 1-disubstituted ethylene process
WO2012080243A3 (en) Process for the preparation of atovaquone
WO2010134048A3 (en) Topical retinoid solutions

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 11752949

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 11752949

Country of ref document: EP

Kind code of ref document: A2